ArticleClinicoEconomics and outcomes research : CEOR2011
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia.
Article in ClinicoEconomics and outcomes research : CEOR, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 54 citations in OpenAlex.
- Pooled it
- Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials.Schizophrenia bulletin · 2014Pooled it
- Predictors of psychiatric hospitalization during 6 months of maintenance treatment with olanzapine long-acting injection: post hoc analysis of a randomized, double-blind study.BMC psychiatry · 2013Trial
- Hospitalisation rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia.Journal of medical economics · 2013Trial
- Prevalence of treatment-resistant schizophrenia among people with early psychosis and its clinical and demographic correlates.The Australian and New Zealand journal of psychiatry · 2024Article
- Observational
- Hospitalization Rates and Therapy Costs of German Schizophrenia Patients Who are Initiated on Long-Acting Injectable Medication: A Mirror-Image Study.Clinical drug investigation · 2020Article
- Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2018Review
- A systematic literature review of the clinical and health economic burden of schizophrenia in privately insured patients in the United States.ClinicoEconomics and outcomes research : CEOR · 2018Review
- The Cost of Inpatient Care of Schizophrenia and Treatment Schedules Used in German Academic Center: Kiel.The Psychiatric quarterly · 2016Article
- [Advantages and controversies of depot antipsychotics in the treatment of patients with schizophrenia].Der Nervenarzt · 2016Review
- Inpatient resource use and costs associated with switching from oral antipsychotics to aripiprazole once-monthly for the treatment of schizophrenia.Drugs in context · 2016Article
- Observational
- Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis.Journal of medical economics · 2015Article
- Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan.ClinicoEconomics and outcomes research : CEOR · 2015Article
- Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients.Drugs in context · 2015Article
- Approaches to improve adherence to pharmacotherapy in patients with schizophrenia.Patient preference and adherence · 2014Review
- An investigation of economic costs of schizophrenia in two areas of China.International journal of mental health systems · 2013Article
- Patient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophrenia.BMC psychiatry · 2013Article
- Cost prediction of antipsychotic medication of psychiatric disorder using artificial neural network model.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo assess change in hospitalization and cost of care from 6 months pre- to 6 months post-initiation on any depot antipsychotic among schizophrenia patients. PATIENTS AND
methodsUsing a large United States commercial claims and encounters database, patients younger than 65 years diagnosed with schizophrenia were identified. Patients initiated on a depot antipsychotic were studied in a mirror-image design to assess change in hospitalization rates, mean duration hospitalized, and hospitalization cost. McNemar's test and paired t-tests compared the proportions of patients hospitalized and the mean duration. Paired t-test and bootstrapping methods compared costs.
resultsIn these patients (n = 147), psychiatric hospitalizations declined from 49.7% pre-initiation to 22.4% post-initiation (P < 0.001), and the mean hospitalized duration for psychiatric purposes numerically declined from 7.3 to 4.7 days (P = 0.05). Total health care costs declined from $11,111 to $7884 (P < 0.05) driven by reduction in costs for psychiatric hospitalizations from $5384 to $2538 (P < 0.05).
conclusionInitiation of depot antipsychotic therapy appeared to be associated with a decline in hospitalization rates and costs. Current findings suggest that treatment with depot antipsychotics may be a cost-effective option for a subgroup of patients with schizophrenia who are at high risk of nonadherence with their oral antipsychotic medication regimen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.